Antidepressant Selection With Lamotrigine for Depression and Irritability
No antidepressant has demonstrated superiority specifically for combination with lamotrigine for bipolar-spectrum depression or irritability. [1], [2]
For bipolar depression, antidepressants are recommended only as a cautious second-line adjunct and are not recommended as monotherapy. [1], [2]
Medication Selection Algorithm
- Avoid antidepressant monotherapy for bipolar depression. [2]
- Use antidepressants only as a second-line add-on when first-line options are inadequate. [1]
- Prefer selective serotonin reuptake inhibitors (SSRIs) over tricyclic antidepressants because SSRIs are less likely to be associated with switching than TCAs. [3]
- Consider mood-stabilizing optimization or antipsychotic-based strategies for depressive symptoms when appropriate. [1], [4]
Key Evidence Supporting This Recommendation
- The 2018 CANMAT/ISBD bipolar guideline supports adjunctive antidepressant therapy with an antidepressant from the SSRI or bupropion class with lithium or divalproex or with an atypical antipsychotic as a second-line add-on strategy. [1]
- The same guideline advises that antidepressants should be avoided or used cautiously in patients with a history of antidepressant-induced mania or hypomania, current or predominant mixed features, or recent rapid cycling. [1]
- A WHO evidence summary for bipolar depressive episodes recommends an SSRI antidepressant because SSRIs are less likely than tricyclic antidepressants to be associated with switching. [3]
Monotherapy Versus Combination Therapy
- Bipolar depression should not be treated with antidepressant monotherapy. [2]
- Adjunctive antidepressant use is presented as an option for inadequate response to first-line agents, in combination with a mood-stabilizing regimen. [1]
- VA/DoD notes insufficient evidence for or against antidepressants or lamotrigine as monotherapy for acute bipolar depression. [4]
Important Clarifications and Nuances
- Irritability can reflect bipolar spectrum illness, mixed features, anxiety, or comorbid conditions. [1]
- Antidepressant-related mood switching and cycle acceleration risk is a primary safety consideration in bipolar-spectrum depression. [1], [3]
- If antidepressants are used, early discontinuation is recommended when signs of mood switching or cycle acceleration emerge. [1]
Initiation Thresholds and Indications
- Antidepressants should be avoided for depressive symptoms with rapid-cycling bipolar disorder, recent hypomanic episode, or recent functionally impairing rapid mood fluctuations. [3]
- For patients with moderate or severe depressive symptoms in bipolar disorder, SSRIs are recommended to be considered, with monitoring for switching risk. [3]
Common Pitfalls to Avoid
- Antidepressant monotherapy for bipolar depression is a key avoidable strategy. [2]
- Use of antidepressants in the setting of rapid cycling, a recent hypomanic episode, or recent functionally impairing rapid mood fluctuations is a key avoidable strategy. [3]
- Persistent antidepressant continuation after remission increases switching and cycle-acceleration risk, so discontinuation should be considered when depressive symptoms are in remission or significantly less severe for about 8 weeks. [3]
Target Goals of Therapy
- The bipolar treatment goal is reduction of depressive episode severity while minimizing manic switch and cycle acceleration. [1], [3]
- Maintenance goals for bipolar depression include prevention of recurrence of bipolar depressive episodes, for which lamotrigine is recommended in VA/DoD guidance. [4]